SCHEMBL23014100

SCHEMBL23014100

COc1cccc(C(=O)CNS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.66
KAT6A Q92794 5/20 0.63
MEP1B Q16820 1/20 0.61
AKR1C3 P42330 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.55
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
LMNA P02545 3/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KCNA5 P22460 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899544 0.81 KAT6A (0.58) HSD11B1KAT6AMEP1BLMNAALDH1A1
SCHEMBL22779448 0.81 KAT6A (0.67) HSD11B1KAT6AMEP1BL3MBTL1RAB9A
SCHEMBL4175747 0.81 MEP1B (0.75) KAT6AMEP1BAKR1C3L3MBTL1LMNA
SCHEMBL29690031 0.80 HSD11B1 (1.00) HSD11B1KAT6AL3MBTL1NPC1RAB9A
SCHEMBL8889322 0.78 KMT2A (0.68) HSD11B1L3MBTL1NPC1RAB9ALMNA
SCHEMBL19358852 0.78 HTT (0.70) KAT6ANPC1RAB9ALMNAALDH1A1
SCHEMBL7668838 0.78 LMNA (0.68) L3MBTL1NPC1RAB9ALMNAALDH1A1
SCHEMBL5899447 0.78 MMP2 (0.70) KAT6AMEP1BLMNAALDH1A1SMN1; SMN2
SCHEMBL5899462 0.78 KAT6A (0.71) KAT6ALMNAALDH1A1POLBSMN1; SMN2
SCHEMBL9777990 0.77 MEP1B (0.50) KAT6AMEP1BAKR1C3LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND CELLGENTEK CO., LTD. (KR) 2023-05-18 US claimed
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 EP claimed
WO-2021034087-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND 주식회사 셀젠텍 2021-02-25 WO claimed
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND CELLGENTEK CO., LTD. (KR) 2023-05-18 US disclosed
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND CELLGENTEK CO., LTD. (KR) 2023-05-18 US disclosed
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 EP disclosed
EP-4019495-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND Cellgentek Co., Ltd (KR) 2022-06-29 EP disclosed
US-20180222857-A1 ARYL SULFONOHYDRAZIDES MONASH UNIVERSITY (AU) 2018-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222857-A1 ARYL SULFONOHYDRAZIDES FPR3, NCOA3, HAT1 HSD11B1 512/4885KAT6A 130/4885MEP1B 989/4885
US-20230150924-A1 NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND KNTC1, MED1, LEF1 HSD11B1 93/4885KAT6A 137/4885MEP1B 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.